The present study first investigated the deregulated HNRNPH1–PTPN6–PI3K/AKT axis moderated cell growth and apoptosis in CML cells, whereby targeting this pathway may be a therapeutic CML treatment. This evidence concerns the gene HNRNPH1 and chronic myelogenous leukemia, BCR-ABL1 positive.